GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Strata Skin Sciences Inc (NAS:SSKN) » Definitions » Beneish M-Score

Strata Skin Sciences (Strata Skin Sciences) Beneish M-Score : -3.55 (As of May. 13, 2024)


View and export this data going back to 2005. Start your Free Trial

What is Strata Skin Sciences Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -3.55 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Strata Skin Sciences's Beneish M-Score or its related term are showing as below:

SSKN' s Beneish M-Score Range Over the Past 10 Years
Min: -3.65   Med: -3.04   Max: 7.23
Current: -3.55

During the past 13 years, the highest Beneish M-Score of Strata Skin Sciences was 7.23. The lowest was -3.65. And the median was -3.04.


Strata Skin Sciences Beneish M-Score Historical Data

The historical data trend for Strata Skin Sciences's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Strata Skin Sciences Beneish M-Score Chart

Strata Skin Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.96 -3.49 -2.88 -2.45 -3.55

Strata Skin Sciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.45 -2.57 -2.58 -2.82 -3.55

Competitive Comparison of Strata Skin Sciences's Beneish M-Score

For the Medical Devices subindustry, Strata Skin Sciences's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Strata Skin Sciences's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Strata Skin Sciences's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Strata Skin Sciences's Beneish M-Score falls into.



Strata Skin Sciences Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Strata Skin Sciences for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 1.0765+0.528 * 1.0877+0.404 * 0.6656+0.892 * 0.9225+0.115 * 1.062
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0019+4.679 * -0.169412-0.327 * 1.5878
=-3.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $4.44 Mil.
Revenue was 8.689 + 8.852 + 8.25 + 7.567 = $33.36 Mil.
Gross Profit was 4.801 + 4.954 + 4.318 + 4.388 = $18.46 Mil.
Total Current Assets was $15.54 Mil.
Total Assets was $42.02 Mil.
Property, Plant and Equipment(Net PPE) was $12.40 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.90 Mil.
Selling, General, & Admin. Expense(SGA) was $23.46 Mil.
Total Current Liabilities was $12.17 Mil.
Long-Term Debt & Capital Lease Obligation was $15.28 Mil.
Net Income was -3.794 + -1.053 + -3.148 + -2.835 = $-10.83 Mil.
Non Operating Income was -2.284 + 0 + -0.909 + 0 = $-3.19 Mil.
Cash Flow from Operations was 1.506 + -0.997 + 0.175 + -1.203 = $-0.52 Mil.
Total Receivables was $4.47 Mil.
Revenue was 10.602 + 9.413 + 9.105 + 7.041 = $36.16 Mil.
Gross Profit was 6.848 + 5.799 + 4.993 + 4.128 = $21.77 Mil.
Total Current Assets was $15.05 Mil.
Total Assets was $52.27 Mil.
Property, Plant and Equipment(Net PPE) was $10.93 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.69 Mil.
Selling, General, & Admin. Expense(SGA) was $25.39 Mil.
Total Current Liabilities was $13.43 Mil.
Long-Term Debt & Capital Lease Obligation was $8.09 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(4.44 / 33.358) / (4.471 / 36.161)
=0.133102 / 0.123641
=1.0765

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(21.768 / 36.161) / (18.461 / 33.358)
=0.601975 / 0.55342
=1.0877

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (15.543 + 12.404) / 42.016) / (1 - (15.052 + 10.925) / 52.272)
=0.334849 / 0.503042
=0.6656

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=33.358 / 36.161
=0.9225

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(5.688 / (5.688 + 10.925)) / (5.902 / (5.902 + 12.404))
=0.342382 / 0.322408
=1.062

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(23.464 / 33.358) / (25.388 / 36.161)
=0.703399 / 0.702082
=1.0019

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((15.281 + 12.174) / 42.016) / ((8.086 + 13.426) / 52.272)
=0.653442 / 0.41154
=1.5878

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-10.83 - -3.193 - -0.519) / 42.016
=-0.169412

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Strata Skin Sciences has a M-score of -3.55 suggests that the company is unlikely to be a manipulator.


Strata Skin Sciences Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Strata Skin Sciences's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Strata Skin Sciences (Strata Skin Sciences) Business Description

Traded in Other Exchanges
Address
5 Walnut Grove Drive, Suite 140, Horsham, PA, USA, 19044
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. Its primary products include the XTRAC excimer laser and VTRAC lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions. Its operating segment includes Dermatology Recurring Procedures which is the key revenue driver and Dermatology Procedures Equipment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United states.
Executives
Shmuel Gov officer: SVP & General Manager Carlsbad 5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Samuel Rubinstein director 5 WALNUT GROVE DR., SUITE 140, HORSHAM PA 19044
Wayne Cafran director 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
Irit Yaniv director 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
22nw Gp, Inc. 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
22nw Fund Gp, Llc 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Aron R. English 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
22nw, Lp 10 percent owner 590 1ST AVE S, UNIT C1, SEATTLE WA 98104
22nw Fund, Lp 10 percent owner 1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107
Christopher Lesovitz officer: Chief Financial Officer 5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Robert Joseph Moccia director, officer: Chief Executive Officer 5 WALNUT GROVE DRIVE, SUITE 140, HORSHAM PA 19044
William D. Humphries director C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Patricia S Walker director 5540 EKWILL ST STE D, SANTA BARBARA CA 93111
Douglas Strang director 5 WALNUT GROVE DRIVE, STE. 140, HORSHAM PA 19044
Nachum Shamir director 12212 TECHNOLOGY BLVD, AUSTIN TX 78727